- Home
- MTNB vs HCWB Comparison
MTNB vs HCWB Comparison
Compare MTNB & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | HCWB |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.0M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTNB | HCWB |
|---|---|---|
| Price | $0.16 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 703.0K | 146.5K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $119,750.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.25 |
| 52 Week High | $2.14 | $5.61 |
Technical Indicators
Market Signals| Indicator | MTNB | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 35.71 |
| Support Level | N/A | $0.37 |
| Resistance Level | $0.21 | $2.15 |
| Average True Range (ATR) | 0.02 | 0.30 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 26.61 | 5.73 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.